Diagnosing Neuropathic Pain in Patients with Cancer: Comparative Analysis of Recommendations in National Guidelines from European Countries

Pain Practice

Volumn 13, Issue 6, 2013, Pages 433-439

  Piano, Virginie ^a,b   Verhagen, Stans ^b   Schalkwijk, Annelies ^b   Burgers, Jako ^c   Kress, Hans ^d   Treede, Rolf Detlef ^e   Hekster, Yechiel ^b   Lanteri Minet, Michel ^a   Engels, Yvonne ^b   Vissers, Kris ^b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DUTCH COLLEGE OF GENERAL PRACTITIONERS   (Netherlands)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Clinical practice guidelines; CPG; European guidelines; Evidence based medicine; Neuralgia; Pain Assessment

Indexed keywords

OPIATE;

ARTICLE; CANCER PATIENT; CHRONIC PAIN; COMPARATIVE STUDY; DIAGNOSTIC TEST; ELECTROMYOGRAM; EUROPE; EVIDENCE BASED MEDICINE; EVOKED SOMATOSENSORY RESPONSE; HUMAN; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; QUANTITATIVE SENSITIVE TEST; TREATMENT RESPONSE;

EID: 84880046470     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12018     Document Type: Article

References (41)

1. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20:1420-1433.
2. Haanpaa ML, Backonja MM, Bennett MI, Bouhassira D, Cruccu G, Hansson PT, et al. Assessment of neuropathic pain in primary care. Am J Med. 2009;122(10 suppl):S13-S21.
3. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82:263-274.
4. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012;153:359-365.
5. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-1449.
6. Naleschinski D, Baron R, Miaskowski C. Identification and treatment of neuropathic pain in patients with cancer. IASP newsletter. Pain clinical updates. 2012;XX:1-4.
7. Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152:2836-2843.
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
9. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist. 2010;15(suppl 2):13-18.
10. Koike H, Tanaka F, Sobue G. Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations. Curr Opin Neurol. 2011;24:504-510.
11. Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain. 2008;137:473-477.
12. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
13. Backonja MM, Krause SJ. Neuropathic pain questionnaire-short form. Clin J Pain. 2003;19:315-316.
14. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149-158.
15. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36.
16. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17:1010-1018.
17. Freynhagen R, Baron R, Gockel U, Tolle TR. Pain DETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-1920.
18. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-197.
19. Scholz J, Mannion RJ, Hord DE, Griffin RS, Rawal B, Zheng H, et al. A novel tool for the assessment of pain: validation in low back pain. PLoS med. 2009;6:e1000047.
20. Institute of Medicine. Guidelines for Clinical Practice from Development to Use. In: Field MJ, Lohr KN, eds. Committee on Clinical Practice Guidelines. Division of health care services. Institute of medicine. Washington, D.C: National Academy Press; 1992.
21. Piano V, Schalkwijk A, Burgers J, et al. Guidelines for Neuropathic Pain Management in Patients with Cancer: A European Survey and Comparison. Pain Pract. 2012; [epub ahead of print; 16 Oct 2012] doi. 10.1111/j.1533-2500.2012.00602.x.
22. Martinez V, Attal N, Bouhassira D, Lanteri-Minet M. Douleurs neuropathiques chroniques: diagnostic, évaluation et traitement en médecine ambulatoire. Douleurs. 2010;11:3-21.
23. ASL. Raccomandazioni per il controllo del dolore neoplastico. Ravenna: ASL; 2006.
24. AIOM Linea Guida. Terapia del dolore in oncologia. Milano: AIOM Linea Guida; 2008.
25. CBO. Richtlijn diagnostiek en behandeling van pijn bij patienten met kanker. Utrecht: CBO; 2008.
26. Vereniging Integrale Kankercentra. Pijn in de palliatieven fase. Utrecht: Vereniging Integrale Kankercentra; 2008.
27. Nasjonale faglige retlingslinjer. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. Oslo: Nasjonale faglige retlingslinjer; 2007.
28. Den Norske Legeforening Retningslinjer for smertelindring. Oslo, (2008)
29. Plan Nacional para el SNS del MSC. Guía de Práctica Clínica sobre cuidados paliativos. Vitoria-Gasteiz: Plan Nacional para el SNS del MSC; 2008.
30. Scottish Intercollegiate Guidelines Network (SIGN). Control of pain in adults with cancer. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2008; 71p. (SIGN publication; no. 106). [264 references].
31. Field MLK. Clinical Practice Guidelines: Directions for a New Program. Washinton DC: National Academy Press, Institute of Medicine; 1990.
32. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14-27.
33. Feinstein ART. Duckett Jones memorial lecture. The Jones criteria and the challenges of clinimetrics. Circulation. 1982;66:1-5.
34. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002;23:239-255.
35. Au E, Loprinzi CL, Dhodapkar M, Nelson T, Novotny P, Hammack J, et al. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity. J Clin Oncol. 1994;12:2751-2755.
36. Boureau F, Doubrere JF, Luu M. Study of verbal description in neuropathic pain. Pain. 1990;42:145-152.
37. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-596.
38. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9-19.
39. Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage. 1991;6:53-57.
40. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277-284.
41. Davis MP. What is new in neuropathic pain? Support care cancer. 2007;15:363-372.